Mustang Bio (Nasdaq:MBIO) - Aandelenkoers, Nieuws & Analyse

MBIO Overzicht aandelen

Mustang Bio, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op het vertalen van medische doorbraken in cel- en gentherapieën naar potentiële behandelingen voor hematologische kankers, solide tumoren en zeldzame genetische ziekten. Meer informatie

MBIO fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 1.5% per jaar gegroeid

Risicoanalyse

Negatief eigen vermogen

Heeft minder dan 1 jaar cash runway

Heeft geen betekenisvolle marktkapitalisatie ( $10M )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

+ 4 meer risico's

Mustang Bio, Inc. Concurrenten

Imunon

NasdaqCM:IMNN

US$12.0m

Senti Biosciences

NasdaqCM:SNTI

US$9.7m

BioRestorative Therapies

NasdaqCM:BRTX

US$10.4m

Oncotelic Therapeutics

OTCPK:OTLC

US$12.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Mustang Bio
Historische aandelenkoersen
Huidige aandelenkoers	US$0.19
52 Week Hoogtepunt	US$1.66
52 Week Laag	US$0.13
Bèta	1.92
11 maand verandering	-37.09%
3 maanden verandering	-37.21%
1 Jaar Verandering	-86.62%
33 jaar verandering	-99.32%
5 jaar verandering	-99.67%
Verandering sinds IPO	-99.87%

Recent nieuws en updates

Recent updates

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Jun 11

Checking Back In On Mustang Bio

May 26

FDA accepts Mustang Bio's MB-106 application in cancer

May 10

Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

Mar 22

What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Feb 23

Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

Jan 28

Rendement voor aandeelhouders

	MBIO	US Biotechs	US Markt
7D	-9.1%	4.3%	1.6%
1Y	-86.6%	18.8%	32.3%

Rendement versus industrie: MBIO presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 18.8 % opleverde.

Rendement versus markt: MBIO presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.3 % opleverde.

Prijsvolatiliteit

Is MBIO's price volatile compared to industry and market?
MBIO volatility
MBIO Average Weekly Movement	13.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van MBIO is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van MBIO is het afgelopen jaar gedaald van 69% naar 13%, maar is nog steeds hoger dan 75% van de US -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	80	Manny Litchman	www.mustangbio.com

Mustang Bio, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op het vertalen van medische doorbraken in cel- en gentherapieën naar mogelijke behandelingen voor hematologische kankers, solide tumoren en zeldzame genetische ziekten. De pijplijn richt zich op gentherapieprogramma's voor zeldzame genetische aandoeningen, chimere antigeen receptor (CAR) gemanipuleerde T-celtherapieën (CAR T) voor hematologische maligniteiten en CAR T-therapieën voor solide tumoren. Het bedrijf ontwikkelt MB-117 en MB-217, een gentherapieprogramma voor X-gebonden ernstige gecombineerde immunodeficiëntie, een zeldzame genetische aandoening van het immuunsysteem waarbij getroffen patiënten zonder behandeling niet ouder worden dan de kinderleeftijd.

Mustang Bio, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Mustang Bio zich tot de beurswaarde?
MBIO fundamentele statistieken
Marktkapitalisatie	US$9.54m
Inkomsten(TTM)	-US$23.42m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.4x

Koers/Winstverhouding

Is MBIO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MBIO resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$23.42m
Inkomsten	-US$23.42m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.49
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde MBIO op de lange termijn?

Bekijk historische prestaties en vergelijking

MBIO Overzicht aandelen

Beloningen

Risicoanalyse

Mustang Bio, Inc. Concurrenten

NasdaqCM:IMNN

US$12.0m

NasdaqCM:SNTI

US$9.7m

NasdaqCM:BRTX

US$10.4m

OTCPK:OTLC

US$12.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

New major risk - Market cap size

New major risk - Financial position

New major risk - Market cap size

Recent updates

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

New major risk - Market cap size

New major risk - Financial position

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

New major risk - Shareholder dilution

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Price target decreased by 43% to US$10.00

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $3.998428 million.

New minor risk - Share price stability

Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)(1)

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $10.5 million.

New major risk - Financial position

Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Price target decreased by 29% to US$13.00

Mustang Bio, Inc. announced that it has received $4.742942 million in funding

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

uBriGene (Boston) Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Consensus EPS estimates upgraded to US$5.61 loss

Price target decreased by 35% to US$40.75

Consensus EPS estimates fall by 286%

Price target increased by 20% to US$75.00

uBriGene (Boston) Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million.

Mustang Bio, Inc. Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Price target decreased to US$5.00

Insufficient new directors

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of Mb-106, A First-In-Class Cd20-Targeted, Autologous Car T Cell Therapy to Treat B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio: This Horse May Gallop Still

Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat Rag1 Severe Combined Immunodeficiency

Mustang Bio, Inc. Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

Mustang Bio Receives Letter from the Listing Qualifications Staff of Nasdaq

Mustang Bio, Inc. Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

Price target decreased to US$7.40

Mustang Bio, Inc. Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Mustang Bio, Inc. Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Mustang Bio: The Market Is Missing This Opportunity

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio Inc. Announces Updated Interim Phase 1/2 Data for Mb-106, Cd20-Targeted Car T Therapy, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Mustang Bio, Inc. Announces Phase 1 Clinical Trial Combining MB-101 and MB-108 for the Treatment of Glioblastoma

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

Price target decreased to US$8.40

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Price target decreased to US$9.80

Mustang Bio Announces MB-101 (IL13Ra2-targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences